Literature DB >> 15221933

Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human carcinomas.

Panayotis Zacharatos1, Athanassios Kotsinas, Konstantinos Evangelou, Panagiotis Karakaidos, Leandros-V Vassiliou, Nousin Rezaei, Aspasia Kyroudi, Christos Kittas, Eystratios Patsouris, Athanasios G Papavassiliou, Vassilis G Gorgoulis.   

Abstract

E2F-1 is a pivotal transcription factor that integrates signals from a variety of G1/S phase regulators and modulates diverse cellular functions, such as DNA synthesis, repair, mitosis, and apoptosis. Its role in cellular proliferation and apoptosis, as depicted from experimental models and limited reports in human malignancies, remains a matter of debate. Recently, in non-small cell lung cancer, it was observed that E2F-1 overexpression was associated with tumour growth, implying an 'oncogenic' effect. To clarify further the role of E2F-1 in carcinogenesis, the investigation was expanded in four of the most common human malignancies by examining its expression status and putative impact on tumour kinetics. These issues were addressed by immunohistochemical and molecular means in 52 breast carcinomas, 42 prostate adenocarcinomas, 58 colon adenocarcinomas, and 77 superficial bladder transitional cell carcinomas (TCCs). The following results were found: (i). in breast carcinomas, E2F-1 expression correlated with proliferation (p < 0.001) and growth index (p = 0.001); (ii). in prostate adenocarcinomas, absence of E2F-1 was noted, in contrast to its expression in normal and hyperplastic glands; (iii). in colon adenocarcinomas, E2F-1 expression was inversely related to growth index (p = 0.001), being expressed in lesions with increased apoptosis (p = 0.001) and low proliferation (p < 0.001); and (iv) in superficial TCCs, E2F-1 expression correlated with proliferation (p = 0.002). Taken together, these results suggest that E2F-1 has a growth-promoting effect in breast carcinomas and superficial TCC, whereas the opposite seems to be the case for colon and prostate cancer. To interpret the above findings, the status of the pRb and p53 tumour suppressor pathways, which are known to affect E2F-1 activity, was further investigated. The results suggest that the actions of E2F-1 are mainly dependent on the functionality of these pathways. Nevertheless, the data also imply that p53-independent pathways may play a nodal role in the function of E2F-1 in colon cancer. Copyright 2004 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15221933     DOI: 10.1002/path.1582

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  38 in total

1.  Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells.

Authors:  Khanh H Nguyen; Paul Hachem; Li-Yan Khor; Naji Salem; Kelly K Hunt; Peter R Calkins; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

2.  Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity.

Authors:  Yang Yan; Songyan Li; Tingting Jia; Xiaohui Du; Yingxin Xu; Yunshan Zhao; Li Li; Kai Liang; Wentao Liang; Huiwei Sun; Rong Li
Journal:  Tumour Biol       Date:  2015-01-28

3.  Inhibition of aldose reductase prevents growth factor-induced G1-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells.

Authors:  Kota V Ramana; Ravinder Tammali; Satish K Srivastava
Journal:  Mol Cancer Ther       Date:  2010-03-30       Impact factor: 6.261

4.  E2F-1 is overexpressed and pro-apoptotic in human hepatocellular carcinoma.

Authors:  Marina Palaiologou; John Koskinas; Menelaos Karanikolas; Evangelia Fatourou; Dina G Tiniakos
Journal:  Virchows Arch       Date:  2012-03-27       Impact factor: 4.064

Review 5.  E2F transcription factors and digestive system malignancies: how much do we know?

Authors:  Athanasios Xanthoulis; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

6.  Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer.

Authors:  Georgia Velimezi; Michalis Liontos; Konstantinos Vougas; Theodoros Roumeliotis; Jirina Bartkova; Maria Sideridou; Ayguel Dereli-Oz; Maciej Kocylowski; Ioannis S Pateras; Kostas Evangelou; Athanassios Kotsinas; Ines Orsolic; Sladana Bursac; Maja Cokaric-Brdovcak; Vassilis Zoumpourlis; Dimitris Kletsas; George Papafotiou; Apostolos Klinakis; Sinisa Volarevic; Wei Gu; Jiri Bartek; Thanos D Halazonetis; Vassilis G Gorgoulis
Journal:  Nat Cell Biol       Date:  2013-07-14       Impact factor: 28.824

7.  EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation.

Authors:  Roland Hubaux; Kelsie L Thu; Bradley P Coe; Calum MacAulay; Stephen Lam; Wan L Lam
Journal:  J Thorac Oncol       Date:  2013-08       Impact factor: 15.609

8.  Increased E2F-1 expression via tumour cell proliferation and decreased apoptosis are correlated with adverse prognosis in patients with squamous cell carcinoma of the oesophagus.

Authors:  K Yamazaki; M Hasegawa; I Ohoka; K Hanami; A Asoh; T Nagao; I Sugano; Y Ishida
Journal:  J Clin Pathol       Date:  2005-09       Impact factor: 3.411

9.  E2F2 induction in related to cell proliferation and poor prognosis in non-small cell lung carcinoma.

Authors:  Li Chen; Jian Hua Yu; Zhi Hui Lu; Wei Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma.

Authors:  Irene Molina-Privado; María Rodríguez-Martínez; Patricia Rebollo; Daniel Martín-Pérez; María-Jesús Artiga; Javier Menárguez; Erik K Flemington; Miguel A Piris; Miguel R Campanero
Journal:  Cancer Res       Date:  2009-05-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.